产品
编 号：F170839
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1469876-18-3
产品详情
生物活性：
Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer.
体内研究：
Labetuzumab govitecan (总共 1.0 mg，腹腔注射) 可延长 GW-39 肺转移小鼠模型的中位生存期。Labetuzumab govitecan (25 mg/kg，腹腔注射，每周两次，持续 4 周) 可延长皮下 LS174T 异种移植裸鼠的中位生存期。Animal Model:sc LS174T Xenograft in nude mice
Dosage:25 mg/kg
Administration:i.p. twice weekly for 4 weeks
Result:Prolonged median survival.
Animal Model:LS174T tumor xenograft model in nude mice (PK assay)
Dosage:0.25 mg
Administration:i.v.
Result:T1/2: 112.5 h; Cmax: 115 μg/mL; MRT: 147 h.
Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer.
体内研究：
Labetuzumab govitecan (总共 1.0 mg，腹腔注射) 可延长 GW-39 肺转移小鼠模型的中位生存期。Labetuzumab govitecan (25 mg/kg，腹腔注射，每周两次，持续 4 周) 可延长皮下 LS174T 异种移植裸鼠的中位生存期。Animal Model:sc LS174T Xenograft in nude mice
Dosage:25 mg/kg
Administration:i.p. twice weekly for 4 weeks
Result:Prolonged median survival.
Animal Model:LS174T tumor xenograft model in nude mice (PK assay)
Dosage:0.25 mg
Administration:i.v.
Result:T1/2: 112.5 h; Cmax: 115 μg/mL; MRT: 147 h.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备